Morgan Stanley lowered the firm’s price target on Organon (OGN) to $15 from $16 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon acquires rights for Tofidence from Biogen
- Organon, Shanghai Henlius Biotech: EMA validates MAA for HLX11
- Telehealth companies aggressively marketing hair-loss medicine to men, WSJ says
- Organon announes results from analysis of Phase 3 ADORING 3 study
- Organon & Co. Navigates Growth Amidst Challenges